{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:55:12Z","timestamp":1785779712132,"version":"3.56.0"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) can drive negative outcomes after liver transplant (LT). Though valganciclovir (VGC) remains the guideline\u2010recommended standard\u2010of\u2010care, letermovir (LTV) may be beneficial in LT given reduced bone marrow suppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients receiving a LT with moderate\u2010risk CMV serostatus (R+) 6\/1\/2021\u20109\/30\/2024 were evaluated. Patients were assigned to a cohort based on de novo antiviral prophylaxis regimen: VGC or LTV. The primary objective was tolerability and safety of LTV compared to VGC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty\u2010five patients met inclusion criteria: 60 in VGC and 25 in LTV cohorts. Significantly more patients in the LTV cohort completed antiviral prophylaxis (VGC 68.3%\u00a0vs. LTV 92.0%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.02), with conversion to an alternative strategy occurring a median of 58 days post\u2010LT in the VGC cohort. No patients terminated LTV due to intolerance or breakthrough. Patients in the VGC cohort were more likely to experience post\u2010LT leukopenia (VGC 81.7%\u00a0vs. LTV 52.0%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.005) and neutropenia (VGC 50.0%\u00a0vs. LTV 24.0%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.03), as well as require GCSF support (VGC 25.0%\u00a0vs. LTV 4.0%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.024). Patients in the LTV cohort tolerated significantly higher total daily doses (TDD) of mycophenolate at 3 (VGC 1750\u00a0mg vs. LTV 2000\u00a0mg,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.005) and 6 (VGC 1000\u00a0mg vs. LTV 2000\u00a0mg,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.04) months post\u2010LT. Incidence of CMV viremia and acute rejection through 1\u2010year post\u2010LT was not significantly different between cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>De novo LTV for CMV prophylaxis in seropositive LT recipients appears to be safe and efficacious. LTV is more likely to be completed compared to VGC and is associated with less myelosuppressive toxicity, allowing for higher doses of mycophenolate. Future studies are needed to definitively evaluate the impact of LTV on rejection rates and transplant outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ctr.70597","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:30:56Z","timestamp":1781530256000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improved Tolerability of De Novo Letermovir Over Valganciclovir for Cytomegalovirus Prophylaxis in Seropositive Liver Transplant Recipients"],"prefix":"10.1111","volume":"40","author":[{"given":"Hanna L.","family":"Kleiboeker","sequence":"first","affiliation":[{"name":"Department of Pharmacy University of Wisconsin Hospital and Clinics  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian L.","family":"Descourouez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Wisconsin Hospital and Clinics  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris M.","family":"Saddler","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Wisconsin\u2010Madison School of Medicine and Public Health University of Wisconsin Hospital and Clinics  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Al\u2010Adra","sequence":"additional","affiliation":[{"name":"Department of Surgery University of Wisconsin\u2010Madison School of Medicine and Public Health University of Wisconsin Hospital and Clinics  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Rice","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Wisconsin\u2010Madison School of Medicine and Public Health University of Wisconsin Hospital and Clinics  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret R.","family":"Jorgenson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Wisconsin Hospital and Clinics  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2025.01.022"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-012-0292-2"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.23460"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399\u20103062.2006.00122.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000005374"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890410524"},{"key":"e_1_2_8_9_1","unstructured":"Highlights of Prescribing Information: PREVYMIS. Accessed January 2 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209939s012 209940s011lbl.pdf."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.9106"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.70169"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.70423"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241307383"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2005.00375.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019847231"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13864"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20417"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14635"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2024.100900"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14208"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182845f6c"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399\u20100012.2007.00788.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.34969"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i41.6674"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0102\u201067202015000300017"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218783245"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.10.005"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.70597","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ctr.70597","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.70597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:25:01Z","timestamp":1785777901000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ctr.70597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/ctr.70597"],"URL":"https:\/\/doi.org\/10.1111\/ctr.70597","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2026-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70597"}}